With the emergence of new therapies that can help patients with HER2-low breast cancer, it’s critical to accurately diagnose and report a patient’s HER2 status to ensure appropriate treatment selection.
To reinforce clinical practice guidelines and help pathologists and laboratory professionals hone their diagnostic skills, ASCP launched a new microlearning series,
Challenges in Testing Across the HER2+ Breast Cancer Spectrum. This 1.0 CME/CMLE credit-bearing activity is funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
ASCP Chief Officer of Medical Quality Ali Brown, MD, FASCP, underscored the importance of adhering to clinical practice guidelines in order to provide an accurate diagnosis and optimize patient care. “With the recent approval of trastuzumab deruxtecan for HER2-low breast cancer, it is critical that pathologists accurately diagnose and report a patient's HER2 status to ensure they receive the right therapy they need,” she says.
ASCP’s new microlearning series is case based and question driven, providing participants a few questions per week via email via the Qstream platform that they can answer to help them sharpen their HER2 interpretation skills using practical examples of breast cancer patient scenarios.
Swikrity U. Baskota, MD, assistant professor of pathology and cell biology at Columbia University Medical Center, and a faculty member (Dr. Poonam Vohra, MD) in ASCP’s microlearning series, note the innovative microlearning format is designed to accommodate the schedules of busy laboratory team members, as they can spend just a few minutes a day answering questions and reviewing immediate feedback based on their responses.
This case-based microlearning activity includes the following topics:
• Best practices in IHC interpretation across the HER2 spectrum
• Clinical practice guidelines for IHC and ISH testing
• The science and emerging evidence around HER2-low breast cancer
• HER2 classification, tracking, and reporting considerations
• Emerging treatment options for patients with HER2-low breast cancer
• The critical importance of communication within the multidisciplinary cancer care team
To learn more about the microlearning series, visit
ASCP’s HER2-low Breast Cancer Education and Resources page.
